Actor Portrayal

Common administration and CPT codes for RotaTeq

Vaccines for Children Program

RotaTeq is available through the Vaccines for Children (VFC) Program for children who qualify. Check with your state or local VFC Program to learn more about the specific products available to your practice.1

CPT and ICD-10-CM codes

Below is a list of codes that may be relevant for RotaTeq and its administration. The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes.

This information is subject to change. Merck cautions that payer coding requirements vary and can frequently change, so it’s important to regularly check with each payer as to payer-specific requirements.

You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Merck makes no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.

CPT code for RotaTeq2

CPT codeProduct code
90680RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent)

Vaccine administration codes3

CPT codeProduct code
90460Product administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each product or toxoid component administered.
+90461Product administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure).
90471Product administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid).
+90472Product administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid). (List separately in addition to code for primary procedure).
ICD-10-CM code4
Z23
Effective for dates of service on or after October 1, 2025, encounter for immunization

Plan coding requirements may vary, so it is important to check with each plan as to plan-specific requirements. For claim submission procedures regarding government programs (eg, Medicaid), contact the appropriate program representative

ICD-10-CM, International Classification of Diseases and Related Health Problems, Tenth Revision, Clinical Modification.

CPT, Current Procedural Terminology.
CPT is a registered trademark of the American Medical Association. CPT codes are effective as of May 2025.


References

  1. Centers for Disease Control and Prevention. Current CDC Vaccine Price List. Last updated May 1, 2026. Accessed May 11, 2026. https://www.cdc.gov/vaccines- for-children/php/price-list/index.html?l
  2. Centers for Disease Control and Prevention. Immunization information systems (IIS). CPT codes mapped to CVX codes. Last reviewed April 17, 2026. Accessed April 30, 2026. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt
  3. American Academy of Pediatrics. Coding for pediatric preventative care. Accessed January 16, 2026. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf
  4. Centers for Medicare & Medicaid Services (U.S.). ICD-10-CM Official Guidelines for Coding and Reporting FY 2025. Updated July 10, 2025. Accessed February 10, 2026. https://stacks.cdc.gov/view/cdc/250974
ExternalSitePopup

Indications and Usage

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Selected Safety Information

RotaTeq is contraindicated in infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

RotaTeq is contraindicated in infants with Severe Combined Immunodeficiency Disease (SCID). These infants should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

RotaTeq is contraindicated in infants with a history of intussusception. These infants should not receive RotaTeq.

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.

Indications and Usage
Selected Safety Information

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age.

Selected Safety Information

RotaTeq is contraindicated in infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

RotaTeq is contraindicated in infants with Severe Combined Immunodeficiency Disease (SCID). These infants should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID.

RotaTeq is contraindicated in infants with a history of intussusception. These infants should not receive RotaTeq.

No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised.

In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days.

No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders.

Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the accompanying Prescribing Information. The Patient Product Information also is available.